Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus carboplatin and etoposide in untreated extensive-stage small cell lung cancer
2019-001146-17Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Roche. Primary endpoint: Incidence of serious adverse events related to treatment. Started Jun 2021; status: completed.
02
Drugs
atezolizumabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2019-001146-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001146-17.